These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29278353)

  • 1. Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials.
    Kang SH; Gogas BD; Jeon KH; Park JS; Lee W; Yoon CH; Suh JW; Hwang SS; Youn TJ; Chae IH; Kim HS
    EuroIntervention; 2018 Mar; 13(16):1904-1913. PubMed ID: 29278353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.
    Ali ZA; Gao R; Kimura T; Onuma Y; Kereiakes DJ; Ellis SG; Chevalier B; Vu MT; Zhang Z; Simonton CA; Serruys PW; Stone GW
    Circulation; 2018 Jan; 137(5):464-479. PubMed ID: 29089314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
    EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
    Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three to four years outcomes of the absorb bioresorbable vascular scaffold versus second-generation drug-eluting stent: A meta-analysis.
    Goel S; Pasam RT; Chava S; Sharma A; Malik BA; Ayzenberg S; Frankel R; Shani J; Gidwani U
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):216-223. PubMed ID: 31002216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Galasso G; Dudek D; De Luca G
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):813-824. PubMed ID: 31730255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
    Kereiakes DJ; Ellis SG; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; Tan SH; Ediebah DE; Simonton C; Stone GW;
    Circulation; 2019 Dec; 140(23):1895-1903. PubMed ID: 31553222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
    Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
    Stone GW; Gao R; Kimura T; Kereiakes DJ; Ellis SG; Onuma Y; Cheong WF; Jones-McMeans J; Su X; Zhang Z; Serruys PW
    Lancet; 2016 Mar; 387(10025):1277-89. PubMed ID: 26825231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial.
    Xu B; Yang Y; Han Y; Huo Y; Wang L; Qi X; Li J; Chen Y; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Popma JJ; Gao R; Stone GW
    EuroIntervention; 2018 Aug; 14(5):e554-e561. PubMed ID: 30082268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
    Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.